Sonnet Biotherapeutics (NYSE: SONN) — Perfil da empresa, notícias e dados financeiros
Sonnet Biotherapeutics is a biopharmaceutical company focused on developing therapies for oncological and immunological conditions.
Sonnet Biotherapeutics
Sonnet Biotherapeutics (NASDAQ:SONN) is a biopharmaceutical company engaged in developing innovative therapies with a focus on oncological and immunological conditions. Leveraging its proprietary Fully Human Albumin Binding (F H AB) technology, Sonnet aims to create biologic drugs with enhanced efficacy and reduced toxicity, providing new treatment options for patients suffering from severe diseases. The company is committed to advancing its pipeline through rigorous scientific research, strategic collaborations, and clinical development programs. Its objective is to address unmet medical needs by bringing forth novel therapeutics that can offer meaningful improvements in patients' lives.
Resumo
Operações
Produtos e/ou serviços de Sonnet Biotherapeutics
- SON-1010 (IL-12Fc): A fusion protein for cancer treatment, leveraging interleukin-12 to boost the immune system's ability to fight tumors.
- SON-1210 (IL-15Fc): Focuses on enhancing the body's natural killer (NK) and T cells' capabilities against cancer through an interleukin-15 fusion protein.
- SON-081 (Low Dose IL-6): Developed for the treatment of peripheral neuropathy, specifically targeting diabetic peripheral neuropathy through low dose interleukin-6.
- SON-080 (Low Dose IL-6): Aimed at treating chemotherapy-induced peripheral neuropathy, utilizing a low dose of interleukin-6 to mitigate symptoms.
- Bispecific Antibody Therapies: Innovative therapies combining two different antibodies to target multiple cancer pathways simultaneously.
- Immunotherapy Platforms: Advanced technology platforms designed to enhance the development of next-generation immunotherapies for cancer.
equipe executiva do Sonnet Biotherapeutics
- Mr. Raghu RaoInterim CEO & Director
- Dr. John K. Cini Ph.D.Chief Scientific Officer & Co-Founder
- Mr. Donald J. Griffith CPA, CPACFO & Director
- Dr. Stephen J. McAndrew Ph.D.President & Chief Business Officer
- Dr. Gael Hedou Ph.D.Chief Operating Officer
- Ms. Susan DexterChief Technical Officer
- Dr. Richard T. Kenney FACP, M.D.Chief Medical Officer
- Mr. Manuel DafonsecaHead of Clinical Operations
Principais indicadores financeiros
Resultados divulgados pela Sonnet Biotherapeutics.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1 mi | -15,8 mi | -16,1 mi | |
| 18,6 mil | -11,8 mi | -7,4 mi | |
| 147,8 mil | -18,8 mi | -18,8 mi | |
| 349,9 mil | -29,7 mi | -29,8 mi |